"In the first month of using IN-PART, we have received interest from senior R&D contacts at two world leading Pharmaceutical companies regarding one of our technologies posted. Discussions have taken place with one of the companies which will be followed by interaction with a relevant technical contact under CDA. We …

"Through IN-PART, we have been able to establish an ongoing relationship with a large multinational pharmaceutical company. While the initial introduction centered on a drug screening platform, those discussions have branched into other areas. We have hosted several members of their team for various meetings and events, and look forward …